Sugammadex (sodium)

Sugammadex (sodium) (CAS No.: 343306-79-6) is a fully synthetic gamma cyclodextrin derivative and selective steroidal neuromuscular blocker binding agent that is broadly categorized as a chemical biology and pharmacology research tool for studying host guest recognition, reversal of neuromuscular blockade related biology, and organ injury modulation in preclinical systems; mechanistically, it acts primarily through high affinity supramolecular encapsulation of aminosteroidal neuromuscular blocking compounds rather than direct receptor agonism or antagonism, thereby reducing the free fraction of these ligands and altering downstream cholinergic transmission dynamics in experimental models, and published research descriptions generally characterize this interaction as occurring in the nanomolar to micromolar activity range depending on assay format, matrix composition, and analyte identity; in life sciences workflows, it is commonly used to investigate pharmacologic sequestration mechanisms, exposure response relationships, and recovery kinetics in biochemical assays, cultured cell contexts, and animal paradigms including ischemia reperfusion associated renal injury research where protective effects have been explored at the experimental level, while concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, species differences, endpoint selection, and whether the study emphasis is mechanistic validation, comparative screening, or translational hypothesis generation within non clinical biomedical research settings.